# Immediate Therapeutic Effects of Diquafosol and Rebamipide in Dry Eye Disease

> **NCT07297316** · PHASE4 · COMPLETED · sponsor: **Korea University Anam Hospital** · enrollment: 30 (actual)

## Conditions studied

- Dry Eye Disease (DED)

## Interventions

- **DRUG:** 3% diquafosol (right eye) and 2% rebamipide (left eye)
- **DRUG:** 2% rebamipide (right eye) and 3% diquafosol (left eye)

## Key facts

- **NCT ID:** NCT07297316
- **Lead sponsor:** Korea University Anam Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-10-03
- **Primary completion:** 2024-08-30
- **Final completion:** 2024-08-30
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2025-12-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07297316

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07297316, "Immediate Therapeutic Effects of Diquafosol and Rebamipide in Dry Eye Disease". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07297316. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*